Shandong Bailong Chuangyuan Bio-tech Co., Ltd.
2025 Annual Performance Express Report Announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and shall be individually and jointly liable for the truthfulness, accuracy and completeness of the content.
The main financial data of 2025 contained in this announcement are preliminary accounting data, unaudited by a certified public accounting firm. The specific data shall be subject to those disclosed in the company's 2025 Annual Report. Investors are reminded of investment risks.
I. Main Financial Data and Indicators for 2025
Unit: Ten Thousand Yuan
|
Items |
Current Reporting Period |
Same Period of Last Year |
Change Rate (%) |
|
Total Operating Income |
137,905.37 |
115,165.23 |
19.75 |
|
Operating Profit |
43,221.56 |
28,512.74 |
51.59 |
|
Total Profit |
43,163.13 |
28,530.83 |
51.29 |
|
Net Profit Attributable to Shareholders of Listed Company |
36,578.32 |
24,559.85 |
48.94 |
|
Net Profit Attributable to Shareholders of Listed Company Excluding Non-Recurring Gains and Losses |
36,059.41 |
23,133.89 |
55.87 |
|
Basic Earnings Per Share (Yuan) |
0.87 |
0.58 |
50.00 |
|
Weighted Average Return on Net Assets (%) |
19.35 |
15.42 |
Increased by 3.93 percentage points |
|
Items |
End of Current Reporting Period |
Beginning of Current Reporting Period |
Change Rate (%) |
|
Total Assets |
243,530.85 |
201,350.48 |
20.95 |
|
Owners' Equity Attributable to Shareholders of Listed Company |
195,778.70 |
167,923.71 |
16.59 |
|
Share Capital (Ten Thousand Shares) |
42,001.23 |
32,308.64 |
30.00 |
|
Net Assets Per Share Attributable to Shareholders of Listed Company (Yuan) |
4.66 |
5.20 |
-10.32 |
Note: The opening balance of this report is the same as the legally disclosed closing balance of the previous year.
II. Explanation on Operating Performance and Financial Condition
(I) Operating Performance
In 2025, the company maintained normal production and operation, with domestic and foreign businesses carried out smoothly, achieving steady revenue growth and rapid profit growth. During the year, the company achieved total operating income of 137,905.37 ten thousand yuan, a year-on-year increase of 19.75%; operating profit of 43,221.56 ten thousand yuan, a year-on-year increase of 51.59%; total profit of 43,163.13 ten thousand yuan, a year-on-year increase of 51.29%; net profit attributable to shareholders of listed company of 36,578.32 ten thousand yuan, a year-on-year increase of 48.94%; net profit attributable to shareholders of listed company excluding non-recurring gains and losses of 36,059.41 ten thousand yuan, a year-on-year increase of 55.87%; basic earnings per share of 0.87 yuan, a year-on-year increase of 50.00%.
The main reasons are as follows: 1. Optimization and adjustment of the company's product structure: The sales proportion of high-margin Resistant Dextrin products in the dietary fiber series further increased, driving profit growth. 2. Optimization of product costs: Relying on its R&D technology, the company promoted the technological transformation of production processes, optimized the material cost structure, and reduced direct material costs. 3. Improvement of capacity utilization: With the increase in demand for the company's product orders, the capacity utilization rates of the "Annual Output 30,000 Tons of Soluble Dietary Fiber Project" and "Annual Output 15,000 Tons of Crystalline Sugar Project" were further improved.
(II) Financial Condition
As of the end of 2025, the company's financial condition was normal. The total assets of the company were 243,530.85 ten thousand yuan, an increase of 20.95% compared with the beginning of the period; the total share capital was 42,001.23 ten thousand shares, an increase of 30.00% compared with the beginning of the period. The main reason was that the 2024 equity distribution implemented a capital reserve increase of 3 shares for every 10 shares held by all shareholders.
III. Risk Tips
The main financial data of 2025 contained in this announcement are preliminary accounting data, unaudited by a certified public accounting firm. The specific data shall be subject to those disclosed in the company's 2025 Annual Report. Investors are reminded of investment risks.
IV. Supporting Documents
Comparative balance sheets and income statements signed and sealed by the company's principal person-in-charge, person-in-charge of accounting work, and person-in-charge of the accounting institution.
Hereby announced.
Shandong Bailong Chuangyuan Bio-tech Co., Ltd. Board of Directors
January 23, 2026
